Clinical Trial

Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction

Study acronym: DUP-TIRZSEMA
Completed
View on ClinicalTrials.gov →
Summary
Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-31; most recent amendment 2026-01-29.
Status change: Active, Not Recruiting → Completed 2026-01-29
Trial Details
NCT Number NCT06914141
Lead Sponsor Brigham and Women's Hospital
Conditions Diabetes Mellitus, Type 2, HFpEF - Heart Failure With Preserved Ejection Fraction
Enrollment 28,118 participants
Start Date 2025-01-14
Primary Completion 2025-06-01 (estimated)
Study Completion 2025-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-30